Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Stock Information for Oncolytics Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.